Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 148-158 |
| Number of pages | 11 |
| Journal | JACC: Heart Failure |
| Volume | 2 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 2014 |
Keywords
- B-type natriuretic peptide
- BNP
- Heart failure
- Meta-analysis
- N-terminal pro-B-type natriuretic peptide
- NT-proBNP
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure. A meta-analysis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JACC: Heart Failure, Vol. 2, No. 2, 04.2014, p. 148-158.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure. A meta-analysis
AU - Savarese, G.
AU - Musella, F.
AU - D'Amore, C.
AU - Vassallo, E.
AU - Losco, T.
AU - Gambardella, F.
AU - Cecere, M.
AU - Petraglia, L.
AU - Pagano, G.
AU - Fimiani, L.
AU - Rengo, G.
AU - Leosco, D.
AU - Trimarco, B.
AU - Perrone-Filardi, P.
N1 - Cited By :11 Export Date: 30 July 2016 References: Roger, V.L., Go, A.S., Lloyd-Jones, D.M., Heart disease and stroke statistics--2011 update: a report from the American Heart Association (2011) Circulation, 123, pp. e18-e209; Groenning, B.A., Raymond, I., Hildebrandt, P.R., Nilsson, J.C., Baumann, M., Pedersen, F., Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population (2004) Heart, 90, pp. 297-303; Hartmann, F., Packer, M., Coats, A.J., Prognostic impact of plasma N-terminal natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial (2004) Circulation, 110, pp. 1780-1786; Seino, Y., Ogawa, A., Yamashita, T., Application of NT pro-BNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure (2004) Eur J Heart Fail, 6, pp. 295-300; Yamamoto, K., Burnett, J.C., Jougasaki, M., Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy (1996) Hypertension, 28, pp. 988-994; Maeda, K., Tsutamoto, T., Wada, A., Hisanaga, T., Kinoshita, M., Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction (1998) Am Heart J, 135, pp. 825-832; Kazanegra, R., Cheng, V., Garcia, A., Arapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study (2001) JCard Fail, 7, pp. 21-29; McMurray, J.J., Adamopoulos, S., Anker, S.D., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC (2012) Eur Heart J, 33, pp. 1787-1847; Bettencourt, P., Azevedo, A., Pimenta, J., Friões, F., Ferreira, S., Ferreira, A., N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients (2004) Circulation, 110, pp. 2168-2174; Michtalik, H.J., Yeh, H.C., Campbell, C.Y., Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure (2011) Am J Cardiol, 107, pp. 1191-1195; Anand, I.S., Fisher, L.D., Chiang, Y.T., Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT) (2003) Circulation, 107, pp. 1278-1283; Latini, R., Masson, S., Wong, M., Incremental prognostic value of changes in B-type natriuretic peptide in heart failure (2006) Am J Med, 119, pp. e23-e30; Masson, S., Latini, R., Anand, I.S., Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial) (2008) JAm Coll Cardiol, 16 (52), pp. 997-1003. , Val-HeFT Investigators; Yan, R.T., White, M., Yan, A.T., Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both (2005) Am J Cardiol, 96, pp. 698-704; Wessler, B.S., Kramer, D.G., Kelly, J.L., Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction (2011) Circ Heart Fail, 4, pp. 578-588; Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement (2009) Ann Intern Med, 151, pp. 264-269. , PRISMA Group; Savarese, G., Paolillo, S., Costanzo, P., Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials (2012) JAm Coll Cardiol, 60, pp. 1192-1201; Detsky, A., Naylor, C., O'Rourke, K., McGeer, A., L'Abbé, K., Incorporating variations in the quality of individual randomized trials into meta-analysis (1992) JClin Epidemiol, 45, pp. 255-265; Savarese, G., Costanzo, P., Cleland, J.G., Ameta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure (2013) JAm Coll Cardiol, 61, pp. 131-142; Davies, H.T., Crombie, I.K., Tavakoli, M., When can odds ratios mislead? (1998) BMJ, 316, pp. 989-991; Sharp, S., Sterne, J., (1998) Stata Tech Bull, 7, pp. 100-108. , Meta-analysis; Sharp, S.J., Meta-analysis regression (1998) Stata Tech Bull, 42, pp. 16-22; Thompson, S.G., Sharp, S.J., Explaining heterogeneity in meta-analysis: a comparison of methods (1999) Stat Med, 18, pp. 2693-2708; Tobias, A., Assessing the influence of a single study in meta-analysis (1999) Stata Tech Bull, 47, pp. 15-17; Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test (1997) BMJ, 315, pp. 629-634; Taylor, A.L., Ziesche, S., Yancy, C., Combination of isosorbide dinitrate and hydralazine in blacks with heart failure (2004) NEngl J Med, 351, pp. 2049-2057; Abulhul, E., McDonald, K., Martos, R., Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide (2012) Clin Ther, 34, pp. 91-100; Boccanelli, A., Mureddu, G.F., Cacciatore, G., Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results (2009) Eur J Heart Fail, 11, pp. 68-76; Gheorghiade, M., Böhm, M., Greene, S.J., Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial (2013) JAMA, 309, pp. 1125-1135; Bielecka-Dabrowa, A., Goch, J.H., Mikhailidis, D.P., Rysz, J., Maciejewski, M., Banach, M., The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy (2009) Med Sci Monit, 15, pp. MS12-MS23; Cleland, J.G., Daubert, J.C., Erdmann, E., The effect of cardiac resynchronization on morbidity and mortality in heart failure (2005) NEngl J Med, 352, pp. 1539-1549; Hartmann, F., Packer, M., Coats, A.J., NT-proBNP in severe chronicheart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy (2004) Eur J Heart Fail, 6, pp. 343-350; Krum, H., Ashton, E., Reid, C., Double-blind, randomized, placebo-controlled study of high-dose HMG coA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure (2007) JCard Fail, 13, pp. 1-7; Schou, M., Gustafsson, F., Videbaek, L., Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar) (2013) Eur Heart J, 34, pp. 432-442; Paterna, S., Di Pasquale, P., Parrinello, G., Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study (2005) JAm Coll Cardiol, 45, pp. 1997-2003; Januzzi, J.L., Rehman, S.U., Mohammed, A.A., Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction (2011) JAm Coll Cardiol, 58, pp. 1881-1889; McKelvie, R.S., Yusuf, S., Pericak, D., Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators (1999) Circulation, 100, pp. 1056-1064; Pfisterer, M., Buser, P., Rickli, H., BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial (2009) JAMA, 301, pp. 383-392; Toblli, J.E., Lombraña, A., Duarte, P., Di Gennaro, F., Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency (2007) JAm Coll Cardiol, 50, pp. 1657-1665; Troughton, R.W., Frampton, C.M., Yandle, T.G., Espiner, E.A., Nicholls, M.G., Richards, A.M., Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations (2000) Lancet, 355, pp. 1126-1130; Cohn, J.N., Tognoni, G., Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure (2001) NEngl J Med, 345, pp. 1667-1675; Wojnicz, R., Nowak, J., Szyguła-Jurkiewicz, B., Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial (2006) Am Heart J, 152, pp. e1-e7; Wojnicz, R., Wilczek, K., Nowalany-Kozielska, E., Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels (2006) Am J Cardiol, 97, pp. 899-904; Yamada, T., Node, K., Mine, T., Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study (2007) Am Heart J, 153, pp. e1-e8; (2013), http://handbook.cochrane.org/, Cochrane Handbook for Systematic Reviews of Interventions. In: Higgins JPT, Green S, editors. Version 5.1.0 (updated March 2011). Available at: Accessed August 24Kramer, D.G., Trikalinos, T.A., Kent, D.M., Antonopoulos, G.V., Konstam, M.A., Udelson, J.E., Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a metaanalytic approach (2010) JAm Coll Cardiol, 56, pp. 392-406; Lainchbury, J.G., Troughton, R.W., Strangman, K.M., N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial (2009) JAm Coll Cardiol, 55, pp. 53-60; Jourdain, P., Jondeau, G., Funck, F., Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study (2007) JAm Coll Cardiol, 49, pp. 1733-1739; Berger, R., Moertl, D., Peter, S., N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study (2010) JAm Coll Cardiol, 55, pp. 645-653; Karlström, P., Alehagen, U., Boman, K., Dahlström, U., Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome (2011) Eur J Heart Fail, 13, pp. 1096-1103. , UPSTEP-study group; Felker, G.M., Hasselblad, V., Hernandez, A.F., O'Connor, C.M., Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials (2009) Am Heart J, 158, pp. 422-430; Savarese, G., Trimarco, B., Dellegrottaglie, S., Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials (2013) PLoS One, 8, pp. e58287; Franzini, M., Masotti, S., Prontera, C., Systematic differences between BNP immunoassays: comparison of methods using standard protocols and quality control materials (2013) Clin Chim Acta, 424, pp. 287-291
PY - 2014/4
Y1 - 2014/4
N2 - Objectives: The goal of this study was to explore the association between changes in B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) plasma levels and risk of hospital admission for heart failure (HF) worsening in patients with chronic HF. Background: The relationship between BNP and NT-proBNP plasma levels and risk of cardiovascular events in patients with chronic HF has been previously demonstrated. However, it is unclear whether changes in BNP and NT-proBNP levels predict morbidity in patients with chronic HF. Methods: The MEDLINE, Cochrane, ISI Web of Science, and SCOPUS databases were searched for papers about HF treatment up to August 2013. Randomized trials enrolling patients with systolic HF, assessing BNP and/or NT-proBNP at baseline and at end of follow-up, and reporting hospital stay for HF were included in the analysis. Meta-regression analysis was performed to test the relationship between BNP and NT-proBNP changes and the clinical endpoint. Sensitivity analysis was performed to assess the influence of baseline variables on results. Egger's linear regression was used to assess publication bias. Results: Nineteen trials enrolling 12,891 participants were included. The median follow-up was 9.5 months (interquartile range: 6 to 18 months), and 22% of patients were women. Active treatments significantly reduced the risk of hospital stay for HF worsening. In meta-regression analysis, changes in BNP and NT-proBNP were significantly associated with risk of hospital stay for HF worsening. Results were confirmed by using sensitivity analysis. No publication bias was detected. Conclusions: In patients with HF, reduction of BNP or NT-proBNP levels was associated with reduced risk of hospital stay for HF worsening. © 2014 American College of Cardiology Foundation.
AB - Objectives: The goal of this study was to explore the association between changes in B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) plasma levels and risk of hospital admission for heart failure (HF) worsening in patients with chronic HF. Background: The relationship between BNP and NT-proBNP plasma levels and risk of cardiovascular events in patients with chronic HF has been previously demonstrated. However, it is unclear whether changes in BNP and NT-proBNP levels predict morbidity in patients with chronic HF. Methods: The MEDLINE, Cochrane, ISI Web of Science, and SCOPUS databases were searched for papers about HF treatment up to August 2013. Randomized trials enrolling patients with systolic HF, assessing BNP and/or NT-proBNP at baseline and at end of follow-up, and reporting hospital stay for HF were included in the analysis. Meta-regression analysis was performed to test the relationship between BNP and NT-proBNP changes and the clinical endpoint. Sensitivity analysis was performed to assess the influence of baseline variables on results. Egger's linear regression was used to assess publication bias. Results: Nineteen trials enrolling 12,891 participants were included. The median follow-up was 9.5 months (interquartile range: 6 to 18 months), and 22% of patients were women. Active treatments significantly reduced the risk of hospital stay for HF worsening. In meta-regression analysis, changes in BNP and NT-proBNP were significantly associated with risk of hospital stay for HF worsening. Results were confirmed by using sensitivity analysis. No publication bias was detected. Conclusions: In patients with HF, reduction of BNP or NT-proBNP levels was associated with reduced risk of hospital stay for HF worsening. © 2014 American College of Cardiology Foundation.
KW - B-type natriuretic peptide
KW - BNP
KW - Heart failure
KW - Meta-analysis
KW - N-terminal pro-B-type natriuretic peptide
KW - NT-proBNP
UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897493907&partnerID=40&md5=754a16bcaa6f2ca252dac055c43681e9
U2 - 10.1016/j.jchf.2013.11.007
DO - 10.1016/j.jchf.2013.11.007
M3 - Article
VL - 2
SP - 148
EP - 158
JO - JACC: Heart Failure
JF - JACC: Heart Failure
IS - 2
ER -